HC Wainwright Reaffirms Buy Rating for Spero Therapeutics (NASDAQ:SPRO)

HC Wainwright reaffirmed their buy rating on shares of Spero Therapeutics (NASDAQ:SPRO) in a report published on Tuesday, Benzinga reports. The firm currently has a $7.00 price target on the stock. HC Wainwright also issued estimates for Spero Therapeutics’ Q3 2024 earnings at ($0.38) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.38) EPS, Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.08) EPS and FY2025 earnings at ($1.08) EPS.

Spero Therapeutics Price Performance

Shares of SPRO stock remained flat at $1.26 on Tuesday. The company had a trading volume of 16,927 shares, compared to its average volume of 220,178. The firm has a 50-day moving average of $1.37 and a 200 day moving average of $1.51. Spero Therapeutics has a 52-week low of $0.99 and a 52-week high of $1.89. The firm has a market capitalization of $68.03 million, a price-to-earnings ratio of 2.93 and a beta of 0.63.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Monday, August 5th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.01. Spero Therapeutics had a net margin of 14.74% and a return on equity of 25.67%. The business had revenue of $10.20 million during the quarter, compared to analyst estimates of $9.80 million. During the same quarter last year, the firm posted ($0.23) earnings per share. Equities analysts forecast that Spero Therapeutics will post -1.27 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Spero Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in Spero Therapeutics by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after acquiring an additional 9,675 shares during the last quarter. Murchinson Ltd. lifted its position in shares of Spero Therapeutics by 1.3% during the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock worth $1,503,000 after purchasing an additional 11,210 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Spero Therapeutics during the first quarter worth $31,000. Acadian Asset Management LLC increased its holdings in Spero Therapeutics by 40.6% in the second quarter. Acadian Asset Management LLC now owns 1,071,860 shares of the company’s stock valued at $1,392,000 after buying an additional 309,262 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in Spero Therapeutics in the fourth quarter valued at $1,570,000. Hedge funds and other institutional investors own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.